Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study
Table 1
Baseline characteristics.
Characteristic
Warfarin plus enoxaparin
Rivaroxaban
()
()
Male [% ()]
49 (40)
59 (45)
Age (years ± SD)
63 ± 15
55 ± 15
Classification [% ()]
Stable
74 (61)
79 (60)
Submassive
23 (19)
18 (14)
Massive
2 (2)
3 (2)
CrCl admission (mL/minute ± SD)
71 ± 24
80 ± 28
Hgb admission (gm/dL ± SD)
13 ± 2.0
13 ± 2.0
BMI (kg/m2 ± SD)
32 ± 9.0
32 ± 8.4
HFrEF [% ()]
4 (3)
3 (2)
DM [% ()]
23 (19)
11 (8)
HTN [% ()]
63 (52)
49 (37)
CAD [% ()]
15 (12)
3 (2)
History DVT/PE [% ()]
23 (19)
20 (15)
INR discharge (±SD)
1.9 ± 0.9
N/A
INR ≥ 2 at discharge [% ()]
44 (36)
N/A
DM: diabetes mellitus, BMI: body mass index, CAD: coronary artery disease, CKD: chronic kidney disease, CrCl: creatinine clearance, CVA: cerebrovascular accident, DVT: deep vein thrombosis, HFrEF: heart failure with reduced ejection fraction, Hgb: hemoglobin, HTN: hypertension, and PE: pulmonary embolism.